Nomura/Instinet raised its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $96.00 (from $84.00) while maintaining a Buy rating, following the company's fourth quarter earnings report.

Analyst Christopher Marai notes a positive outlook on the shares, as SRPT reported fourth quarter earning per share and revenues above consensus projections, while management affirmed FY18 guidance of $295-$305 million.